ProKidney Corp.PROKNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank40
3Y CAGR-45.3%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-45.3%/yr
Annual compound
Percentile
P40
Within normal range
vs 3Y Ago
0.2x
Contraction
Streak
3 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2024 | 19.64% |
| 2023 | 30.02% |
| 2022 | 77.43% |
| 2021 | 119.82% |
| 2020 | -72.03% |
| 2019 | 0.00% |